文献速递生殖医学产科

MEI1新发双等位基因突变扩展表型至人胚胎停滞和反复种植失败

Novel biallelic mutations in MEI1: expanding the phenotypic spectrum to human embryonic arrest and recurrent implantation failure.
PubMed 文献 · Hum Reprod · 2021-01-01

本研究在7个独立家系的9例原发不孕患者中鉴定出MEI1基因的5种新突变,除已知的反复性葡萄胎外,双等位基因MEI1突变还与早期胚胎停滞和反复种植失败相关。体外实验表明,蛋白截短和错义突变降低MEI1蛋白水平,剪接突变导致异常可变剪接。

要点

  • MEI1双等位基因突变可导致早期胚胎停滞和反复种植失败。
  • MEI1突变类型包括蛋白截短、错义和剪接突变,影响蛋白水平或剪接。
  • MEI1可作为相关不孕表型的潜在遗传诊断标记。

核心结论

  • MEI1双等位基因新突变除引起反复性葡萄胎外,还可导致早期胚胎停滞和反复种植失败。

研究设计与样本

  • 研究纳入7个独立家系的9例原发不孕患者,采用全外显子测序和Sanger测序筛查MEI1突变,并通过体外实验分析突变影响。

主要发现

  • 在9例患者中鉴定出5种MEI1新突变,双等位基因突变与早期胚胎停滞和反复种植失败相关。
  • 蛋白截短和错义突变降低MEI1蛋白水平,剪接突变导致异常可变剪接。

临床怎么用

  • 对反复种植失败或早期胚胎停滞患者可考虑MEI1基因检测,为遗传咨询提供依据。

局限性

  • 缺乏患者卵母细胞的体内数据,确切分子机制尚不清楚,需进一步用敲除或敲入小鼠研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are any novel mutations and corresponding new phenotypes, other than recurrent hydatidiform moles, seen in patients with MEI1 mutations? SUMMARY ANSWER: We identified several novel mutations in MEI1 causing new phenotypes of early embryonic arrest and recurrent implantation failure. WHAT IS KNOWN ALREADY: It has been reported that biallelic mutations in MEI1, encoding meiotic double-stranded break formation protein 1, cause azoospermia in men and recurrent hydatidiform moles in women. STUDY DESIGN, SIZE, DURATION: We first focused on a pedigree in which two sisters were diagnosed with recurrent hydatidiform moles in December 2018. After genetic analysis, two novel mutations in MEI1 were identified. We then expanded the mutational screening to patients with the phenotype of embryonic arrest, recurrent implantation failure, and recurrent pregnancy loss, and found another three novel MEI1 mutations in seven new patients from six families recruited from December 2018 to May 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: Nine primary infertility patients were recruited from the reproduction centers in local hospitals. Genomic DNA from the affected individuals, their family members, and healthy controls was extracted from peripheral blood. The MEI1 mutations were screened using whole-exome sequencing and were confirmed by the Sanger sequencing. In silico analysis of mutations was performed with Sorting Intolerant From Tolerant (SIFT) and Protein Variation Effect Analyzer (PROVEAN). The influence of the MEI1 mutations was determined by western blotting and minigene analysis in vitro. MAIN RESULTS AND THE ROLE OF CHANCE: In this study, we identified five novel mutations in MEI1 in nine patients from seven independent families. Apart from recurrent hydatidiform moles, biallelic mutations in MEI1 were also associated with early embryonic arrest and recurrent implantation failure. In addition, we demonstrated that protein-truncating and missense mutations reduced the protein level of MEI1, while the splicing mutations caused abnormal alternative splicing of MEI1. LIMITATIONS, REASONS FOR CAUTION: Owing to the lack of in vivo data from the oocytes of the patients, the exact molecular mechanism(s) involved in the phenotypes remains unknown and should be further investigated using knock-out or knock-in mice. WIDER IMPLICATIONS OF THE FINDINGS: Our results not only reveal the important role of MEI1 in human oocyte meiosis and early embryonic development, but also extend the phenotypic and mutational spectrum of MEI1 and provide new diagnostic markers for genetic counseling of clinical patients. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Key Research and Development Program of China (2018YFC1003800, 2017YFC1001500, and 2016YFC1000600), the National Natural Science Foundation of China (81725006, 81822019, 81771581, 81971450, and 81971382), the project supported by the Shanghai Municipal Science and Technology Major Project (2017SHZDZX01), the Project of the Shanghai Municipal Science and Technology Commission (19JC1411001), the Natural Science Foundation of Shanghai (19ZR1444500), the Shuguang Program of the Shanghai Education Development Foundation and the Shanghai Municipal Education Commission (18SG03), the Shanghai Health and Family Planning Commission Foundation (20154Y0162), the Strategic Collaborative Research Program of the Ferring Institute of Reproductive Medicine, Ferring Pharmaceuticals and the Chinese Academy of Sciences (FIRMC200507) and the Chongqing Key Laboratory of Human Embryo Engineering (2020KFKT008). No competing interests are declared. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Dong J, Zhang H, Mao X, et al. Novel biallelic mutations in MEI1: expanding the phenotypic spectrum to human embryonic arrest and recurrent implantation failure. Hum Reprod. 2021. PMID: 34037756. doi:10.1093/humrep/deab118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。